<DOC>
	<DOC>NCT00905333</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil®</brief_summary>
	<brief_title>Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Felodipine</mesh_term>
	<criteria>Healthy volunteers BMI &gt; or = 19 and &lt; or = 28 (Dietary Guidelines Advisory Committee, 2005) Not healthy Chronic drug intake</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>candesartan</keyword>
	<keyword>felodipine</keyword>
	<keyword>test formulations</keyword>
	<keyword>Atacand®</keyword>
	<keyword>Splendil®</keyword>
	<keyword>healthy volunteers</keyword>
	<keyword>blood samples</keyword>
	<keyword>after meal intake interaction</keyword>
	<keyword>Kinetic interaction amongst test formulations of Candesartan and Felodipine and the brands Atacand® and Splendil® in healthy volunteers after a fasting period.</keyword>
</DOC>